Clinical Trial: A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

U.S., Sept. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07197554) titled 'A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies' on Aug. 28.

Brief Summary: A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

Study Start Date: Oct. 01

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors Ewing Sarcoma Hepatocellular Carcinoma (HCC) Biliary Tract Cancer (BTC)

Intervention: DRUG: ST-01156

ST-01156 is an orally administered degrader of RBM39, a protein frequently upregulated in cancer

Recruitment Status: NOT_YET_RECRUITING

Sponsor: SEED Therapeutics, Inc.

Disclaimer: Curated by HT Syndication....